Pfizer Inc - Company Profile
Powered by 
All the data and insights you need on Pfizer Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Pfizer Inc Strategy Report
- Understand Pfizer Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View morePfizer Catalyst Calendar
Proactively evaluate Pfizer Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Pfizer Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 15 Aug 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 15 Aug 2019 | Constraining Patent Expiry (US) | Pfizer Inc | PFE | temsirolimus | Central Nervous System; Immunology; Oncology | Anaplastic Thyroid Cancer; B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia); Bladder Cancer; CNS Lymphoma; Follicular Lymphoma; Follicular Thyroid Cancer; Glioblastoma Multiforme (GBM); Hepatocellular Carcinoma; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Lymphoblastic Lymphoma; Malignant Glioma; Mantle Cell Lymphoma; Medullary Thyroid Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Myelodysplastic Syndrome; Ovarian Cancer; Papillary Thyroid Cancer; Peripheral T-Cell Lymphomas (PTCL); Relapsing Remitting Multiple Sclerosis (RRMS); Renal Cell Carcinoma; Rheumatoid Arthritis; Secondary Progressive Multiple Sclerosis (SPMS); T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia); Triple-Negative Breast Cancer (TNBC) | GD Estimates |
| 15 Aug 2019 | Phase III Trial Initiation | International Breast Cancer Study Group; Pfizer Inc | PFE | palbociclib | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) | Clinical Trial Registry |
| 13 Aug 2019 | Phase I Trial Initiation | Pfizer Inc | PFE | ervogastat | Gastrointestinal | Non Alcoholic Fatty Liver Disease (NAFLD); Non-Alcoholic Steatohepatitis (NASH) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward